ES2185307T3 - Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion. - Google Patents

Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion.

Info

Publication number
ES2185307T3
ES2185307T3 ES99901979T ES99901979T ES2185307T3 ES 2185307 T3 ES2185307 T3 ES 2185307T3 ES 99901979 T ES99901979 T ES 99901979T ES 99901979 T ES99901979 T ES 99901979T ES 2185307 T3 ES2185307 T3 ES 2185307T3
Authority
ES
Spain
Prior art keywords
preparation
formula
transferasa
farnesil
piperidinic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99901979T
Other languages
English (en)
Inventor
You Seung Shin
Jong Sung Koh
Hyun Il Lee
Jin Ho Lee
Jong Hyun Kim
Hyun Ho Chung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Corp
Original Assignee
LG Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019980002777A external-priority patent/KR100388789B1/ko
Priority claimed from KR1019980028340A external-priority patent/KR100388792B1/ko
Priority claimed from KR10-1998-0032150A external-priority patent/KR100388794B1/ko
Application filed by LG Chemical Co Ltd filed Critical LG Chemical Co Ltd
Application granted granted Critical
Publication of ES2185307T3 publication Critical patent/ES2185307T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un derivado de piperidina representado por la siguiente fórmula (1) **(Fórmula)** en la que A representa hidrógeno, alquilo inferior o **(Fórmula)** en la que B representa CH2, C=O o SO2, y D representa un radical seleccionado del grupo siguiente: **(Fórmulas)** En la definición para el sustituyente D, m representa un número entero de 0 a 3, n representa un número entero de 1 a 3, X representa hidrógeno, fenilo, fenoxi, alquilo C1-C4, alcoxi C1-C4, halógeno, nitro, o amino que está opcionalmente sustituido con bencilo o alquilo C1-C4, R1 y R2 representan independientemente entre sí hidrógeno, alquilo C1-C4, cicloalquilo C3-C6, alquilo C1-C4 sustituido con cicloalquilo C3-C6, arilo o heteroarilo, E representa hidrógeno, fenilo, naftilo o **(Fórmula)** en la que R3 y R4 representan independientemente entre sí hidrógeno, alquilo C1-C4, arilo **(Fórmula)** (en la que Y representa O o S, n¿ representa un número entero de 2 a 4, y R5 representa alquilo C1-C4), G representa un radical seleccionadodel siguiente grupo: **(Fórmulas)** en la que Z representa O, S, SO2 o N-R6 (en la que R6 representa hidrógeno o alquilo C1-C4), R7 y R8 representan independientemente entre sí hidrógeno, alquilo C1-C4, alcoxi C1-C4, halógeno, ciano, hidroxicarbonilo, aminocarbonilo, aminotiocarbonilo, hidroxi, fenilo o fenoxi o una sal farmacéuticamente aceptable del mismo.
ES99901979T 1998-02-02 1999-02-01 Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion. Expired - Lifetime ES2185307T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR19980002776 1998-02-02
KR1019980002777A KR100388789B1 (ko) 1998-02-02 1998-02-02 피롤구조를갖는파네실전이효소억제제및그의제조방법
KR1019980028340A KR100388792B1 (ko) 1998-02-02 1998-07-14 피페리딘구조를갖는파네실전이효소억제제및그의제조방법
KR10-1998-0032150A KR100388794B1 (ko) 1998-08-07 1998-08-07 피페리딘구조를갖는파네실전이효소억제제및그의제조방법

Publications (1)

Publication Number Publication Date
ES2185307T3 true ES2185307T3 (es) 2003-04-16

Family

ID=27483262

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99901979T Expired - Lifetime ES2185307T3 (es) 1998-02-02 1999-02-01 Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion.

Country Status (12)

Country Link
US (1) US6436960B1 (es)
EP (1) EP1058683B1 (es)
JP (1) JP3283032B2 (es)
CN (1) CN1158277C (es)
AT (1) ATE229017T1 (es)
AU (1) AU745855B2 (es)
BR (1) BR9908545A (es)
CA (1) CA2320233C (es)
DE (1) DE69904302T2 (es)
ES (1) ES2185307T3 (es)
PT (1) PT1058683E (es)
WO (1) WO1999038862A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100388792B1 (ko) * 1998-02-02 2003-09-22 주식회사 엘지생명과학 피페리딘구조를갖는파네실전이효소억제제및그의제조방법
KR100388794B1 (ko) * 1998-08-07 2003-10-10 주식회사 엘지생명과학 피페리딘구조를갖는파네실전이효소억제제및그의제조방법
ATE277039T1 (de) * 1999-04-13 2004-10-15 Lg Chem Investment Ltd Farnesyltransferase-inhibitoren die eine pyrrolstruktur haben und verfahren zu ihrer herstellung
KR20010063274A (ko) * 1999-12-22 2001-07-09 성재갑 〔1-｛〔1-（1,3-벤조디옥솔-5-일메틸-1ｈ-이미다졸-5-일〕메틸｝-4-(1-나프틸)-1ｈ-피롤-3-일〕（4-메틸-1-피페라지닐）메타논의 약학적 조성물
US7035932B1 (en) * 2000-10-27 2006-04-25 Eric Morgan Dowling Federated multiprotocol communication
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
KR100897642B1 (ko) 2002-12-20 2009-05-14 글락소 그룹 리미티드 신경 장애 치료용 벤즈아제핀 유도체
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
WO2005037826A1 (en) 2003-10-17 2005-04-28 Incyte Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
CA2602035C (en) 2005-03-18 2015-06-16 Medimmune, Inc. Framework-shuffling of antibodies
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
AU2007290570C1 (en) 2006-08-28 2013-08-15 Kyowa Kirin Co., Ltd. Antagonistic human LIGHT-specific human monoclonal antibodies
CA2682292A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
SG11201509982UA (es) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
AU2014332442B2 (en) 2013-08-26 2019-12-19 Biontech Research And Development, Inc. Nucleic acids encoding human antibodies to Sialyl-Lewis
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9856324B2 (en) 2014-06-04 2018-01-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
JP6800853B2 (ja) 2014-12-11 2020-12-16 ピエール、ファーブル、メディカマン 抗ｃ１０ｏｒｆ５４抗体およびその使用
KR20250005465A (ko) 2015-03-03 2025-01-09 키맵 리미티드 항체, 용도 및 방법
EP3383911B1 (en) 2015-12-02 2021-01-20 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
KR20200026209A (ko) 2017-06-06 2020-03-10 주식회사 에스티큐브앤컴퍼니 Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI97540C (fi) * 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
SK114094A3 (en) * 1992-03-25 1995-04-12 Pfizer Peptides, method of their producing, their using and pharmaceutical preparation on their base
GB9312806D0 (en) * 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
CA2250353A1 (en) * 1996-04-03 1997-10-09 Christopher J. Dinsmore Inhibitors of farnesyl-protein transferase
CA2250232A1 (en) * 1996-04-03 1997-10-09 Allen I. Oliff A method of treating cancer
JP2000507591A (ja) * 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
EP0944388A4 (en) * 1996-04-03 2001-08-16 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
CA2250192A1 (en) * 1996-04-03 1997-10-09 Chrisopher J. Dinsmore Inhibitors of farnesyl-protein transferase
CA2310629A1 (en) * 1997-11-28 1999-06-10 Tae Hwan Kwak Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof

Also Published As

Publication number Publication date
US6436960B1 (en) 2002-08-20
JP3283032B2 (ja) 2002-05-20
BR9908545A (pt) 2001-10-02
DE69904302D1 (de) 2003-01-16
CN1289331A (zh) 2001-03-28
EP1058683B1 (en) 2002-12-04
CA2320233C (en) 2004-07-27
CN1158277C (zh) 2004-07-21
AU2188699A (en) 1999-08-16
AU745855B2 (en) 2002-04-11
PT1058683E (pt) 2003-04-30
ATE229017T1 (de) 2002-12-15
WO1999038862A1 (en) 1999-08-05
EP1058683A1 (en) 2000-12-13
CA2320233A1 (en) 1999-08-05
DE69904302T2 (de) 2003-08-14
JP2002501918A (ja) 2002-01-22

Similar Documents

Publication Publication Date Title
ES2185307T3 (es) Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion.
BR0108893A (pt) Composição farmacêutica, composto e processo de preparação de compostos
DE69919397D1 (de) Thrombin-inhibitoren
NO950774L (no) Fremgangsmåte for inhibering av bentap og nedsettelse av serumkolesterol
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
KR950017957A (ko) 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
ATE223378T1 (de) Prolineamid-derivate
EP1362846A4 (en) AMINOETHANOL DERIVATIVES
BR9803883A (pt) Derivado de amida.
BR0210874A (pt) Derivados de tiazol-benzamida e composições farmacêuticas para a inibição da proliferação celular e métodos para o seu uso
DE69635996D1 (de) Pharmazeutische zusammensetzungen mit hydroximsäurederivaten
EP1208092A4 (en) SULPHONAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS
BR9916004A (pt) Inibidores de proteinase c de pró-colágeno
ATE277039T1 (de) Farnesyltransferase-inhibitoren die eine pyrrolstruktur haben und verfahren zu ihrer herstellung
NO20023001L (no) Substituerte piperazinderivater som MTP inhibitorer
BR0115454A (pt) Composto de 1-metilcarbapenem ou um sal ou derivado de éster deste farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou de um sal ou derivado de éster deste farmaceuticamente aceitável
HN1997000070A (es) Inhibición de las metaloproteinasas de matriz por acidos 2-((1)-aroilalquil) -4-biaril-4-oxoburiticos
SE9403137D0 (sv) Derivatives of carbohydrates and compositions containing them
ATE286395T1 (de) Antithrombotische mittel
DK0561882T3 (da) Hydroxamsyrederivater, som inhiberer lipoxygenase
HRP20050815A2 (en) 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound
UY26971A1 (es) Nuevos antagonistas de neuroquinina, procedimiento para su preparación y composiciones farmacéuticas que contienen estos compuestos
ECSP055804A (es) Composición farmacéutica
NO20001846L (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer